Satoris | GenomeWeb

Satoris

By Adam Bonislawski
A Stanford University-led research team has identified plasma proteins linked to declines in neurogenesis and impaired learning and memory.

RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.

Satoris will use a panel of 500 signaling proteins and antibody-based quantitative nitrocellulose filter membrane array technology to search for candidate biomarkers for the disease. In May, it launched its first commercial products, protein panels for Alzheimer's disease and dementia.

According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] and thus provide researchers with critical biological information plus leads for further study."

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.